Clinical Trials Logo

Filter by:
  • Completed  
  • Page [1] ·  Next »
NCT ID: NCT06442865 Completed - Diabetic Foot Clinical Trials

AMNIODERM+ Medical Device Clinical Study

AMNIODERM+
Start date: November 16, 2022
Phase:
Study type: Observational

This is retrospectively-prospective clinical trial with medical device AMNIODERM+ intended for the non-healing wounds. Retrospective data will contain information about the subject's history and wound treatment by SoC. Prospective data will contain information about wound treatment by AMNIODERM+®.

NCT ID: NCT06220409 Completed - Sclerosis, Multiple Clinical Trials

Gut Microbiota Composition, Cognitive Function, and Physical Fitness in Multiple Sclerosis Patients

MSDANCE
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The evidence suggests that multiple sclerosis (MS) induces a decline in motor and cognitive function and provokes a shift in gut microbiome composition in patients. Therefore, the purpose of this study is to explore the effect of a 12-week dance class training program on the gut microbiota composition, motor function, and cognitive function of patients with MS. The investigators will also study the following: - The impact of organised physical activity on quality of life - The impact of organised physical activity on body composition and metabolic parameters (e.g., insulin sensitivity, lipid profile, ect.) - The impact of organised physical activity on physical fitness (e.g., VO2max, Power, ect.)

NCT ID: NCT05939791 Completed - Clinical trials for Acute Lymphoblastic Leukemia, Pediatric

Physical Exercise and Dairy Probiotics in Childhood Cancer Survivors

Exerbioall
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to to compare the structure of the intestinal microbiome between children shortly after treatment for acute lymphoblastic leukemia (1-3 years after cancer treatment) and healthy controls. And then to provoke a positive shift of bacterial diversity by physical activity and probiotics in cured pediatric oncology patients with persistent gut microbiome disruptions. The main question[s] it aims to answer are: - Are differences in bacterial richness between healthy controls and pediatric oncology patients ≥12 months after cancer treatment apparent? - Has the combination of physical exercise and probiotics had a positive influence on the structure of the gut microbiome in childhood cancer survivors in remission? Two times per week of physical activity and daily dairy consumption with probiotics will be required of participants for eight weeks.

NCT ID: NCT05827640 Completed - Clinical trials for Comparing Six Different Methods to Obtain Expiratory Time Constant

Expiratory Time Constant in Mechanically Ventilated Patients

Start date: November 15, 2022
Phase:
Study type: Observational

Determining expiratory time constants in mechanically ventilated patients

NCT ID: NCT05827120 Completed - Clinical trials for Acute Deep Venous Thrombosis

Endovascular Therapy in Patients With Acute Deep Vein Thrombosis

LEVANTE
Start date: March 23, 2021
Phase:
Study type: Observational

Despite optimal anticoagulation therapy of patients with proximal deep vein thrombosis (DVT), there is still high number of patients suffering from post-thrombotic syndrome (PTS) due to the chronic venous occlusion, suboptimal collateralization, and venous valvular dysfunction. Last two decades endovascular catheter-based treatment modalities have been tested and used in an attempt to reduce incidence and symptoms of PTS in selected patients. Especially, patients with extensive iliofemoral DVT have an increased risk of PTS. In an effort to accelerate thrombus dissolution or thrombus extraction, the endovascular removal of acute venous thrombus has been introduced as therapeutic option in patients with extensive iliofemoral DVT. Randomized trials of catheter-based strategies for thrombus removal have documented improved vein patency, preserved valves function, and reduced post-thrombotic syndrome. The aim of our study is to evaluate the safety and efficacy of different types of endovascular methods of treatment followed by anticoagulation therapy in patients with acute extensive DVT. Retrospective multicentre analysis of app 100 patients scheduled for endovascular treatment of extensive DVT. The results of mechanical/pharmacomechanical thrombectomy followed by local catheter directed thrombolysis (CDT), will be compared with CDT alone, or with ultrasound-accelerated thrombolysis. The 24-month incidence of PTS assessed by Villalta scoring system, major bleeding complications, the rate of venous recanalization, recurrence of DVT, and other end-points will be evaluated.

NCT ID: NCT05795153 Completed - Clinical trials for Chronic Spontaneous Urticaria

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to rule out an increase of >3mmHg in 24-hour average Systolic Blood Pressure at steady state (Week 4) compared to baseline. ABPM was chosen for the blood pressure assessment in this trial as recommended by the FDA for drugs intended for chronic use (Assessment of Pressor Effects of Drugs Guidance for Industry (FDA 2022)).

NCT ID: NCT05790304 Completed - Hepatic Impairment Clinical Trials

Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects

Start date: February 20, 2023
Phase: Phase 1
Study type: Interventional

This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal female participants with moderate or severe hepatic impairment compared with post-menopausal female participants with normal hepatic function. Participants will be enrolled within the following groups based on their CP classification score as determined at screening: - Group 1: Matched-control healthy participants with normal hepatic function. - Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9). - Group 3: Participants with severe hepatic impairment (CP Class C, score of 10 to 15).

NCT ID: NCT05706623 Completed - Hepatic Impairment Clinical Trials

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Start date: January 30, 2023
Phase: Phase 1
Study type: Interventional

The primary objective is to assess the PK of apraglutide in subjects with hepatic impairment compared with matched control subjects with normal hepatic function following single SC dose administration.

NCT ID: NCT05644691 Completed - Atopic Dermatitis Clinical Trials

Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis

Start date: October 14, 2020
Phase:
Study type: Observational

This study aims at assessing the reduction of consumption of corticosteroids (same mid-potent corticosteroids for all patients) afforded by the use of a specific emollient in comparison to the usual one in subjects suffering from atopic dermatitis.

NCT ID: NCT05483205 Completed - Acne, Adult Clinical Trials

Normaderm Phytosolution Global Observational Study

Start date: July 1, 2019
Phase:
Study type: Observational

The objective of this 3-month observational study was to assess, in 2827 adults, the benefit of NP alone or as adjunctive or maintenance care in mild acne, or as adjunctive care in subjects with moderate acne.